The-308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis

Fabris, M.; Quartuccio, Luca; Fabro, C.; Sacco, S.; Lombardi, S.; Ramonda, R.; Biasi, D.; Punzi, D.; Adami, S.; Olivieri, I.; Curcio, Francesco; De Vita, Salvatore

doi:10.1038/tpj.2015.49

The genetic predisposition to a long-term efficacy of anti-tumor necrosis factor (TNF)alpha treatment in seronegative spondyloarthritis (SpA) was investigated by analysing the possible correlation between several single nucleotide gene polymorphisms and the retention rate of anti-TNF alpha therapies. We compared patients needing to switch the first anti-TNF alpha (Sw, No. 64) within at least 12 months of follow-up with patients not needing to switch (NSw, No. 123), observing at least 6 months of treatment to establish anti-TNF alpha failure, leading to treatment change. Response to treatment was evaluated by standardised criteria (BASDAI for axial involvement, DAS28-EULAR for peripheral involvement). The TNF alpha -308 A allele and the interleukin (IL)-6 -174GG homozygosis resulted as independent biomarkers predicting survival of the first anti-TNF alpha therapy in SpA patients (P = 0.007, odds ratio (OR): 4.4, 95% confidence interval (CI) = 1.5-13.1 and P = 0.035, OR: 2.1, 95% CI = 1.1-4.4). Also, the male gender (P = 0.001, OR: 3.4, 95% CI = 1.6-7.1) associated with the NSw phenotype, whereas no association was found either with the specific diagnosis or the predominant joint involvement.

Titolo:	The-308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis
Autori:	Fabris, M. QUARTUCCIO, Luca Fabro, C. Sacco, S. Lombardi, S. Ramonda, R. Biasi, D. Punzi, D. Adami, S. Olivieri, I. CURCIO, Francesco DE VITA, Salvatore mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2016
Rivista:	PHARMACOGENOMICS JOURNAL
Abstract:	The genetic predisposition to a long-term efficacy of anti-tumor necrosis factor (TNF)alpha treatment in seronegative spondyloarthritis (SpA) was investigated by analysing the possible correlation between several single nucleotide gene polymorphisms and the retention rate of anti-TNF alpha therapies. We compared patients needing to switch the first anti-TNF alpha (Sw, No. 64) within at least 12 months of follow-up with patients not needing to switch (NSw, No. 123), observing at least 6 months of treatment to establish anti-TNF alpha failure, leading to treatment change. Response to treatment was evaluated by standardised criteria (BASDAI for axial involvement, DAS28-EULAR for peripheral involvement). The TNF alpha -308 A allele and the interleukin (IL)-6 -174GG homozygosis resulted as independent biomarkers predicting survival of the first anti-TNF alpha therapy in SpA patients (P = 0.007, odds ratio (OR): 4.4, 95% confidence interval (CI) = 1.5-13.1 and P = 0.035, OR: 2.1, 95% CI = 1.1-4.4). Also, the male gender (P = 0.001, OR: 3.4, 95% CI = 1.6-7.1) associated with the NSw phenotype, whereas no association was found either with the specific diagnosis or the predominant joint involvement.
Handle:	http://hdl.handle.net/11390/1107857
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

File	Descrizione	Tipologia	Licenza
tpj201549.pdf		Versione Editoriale (PDF)	Non pubblico	Accesso ristretto Richiedi una copia

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11390/1107857

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: